These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2146459)

  • 1. Prenatal diagnosis of Down's syndrome: a method for measuring the consistency of women's decisions.
    Thornton JG; Lilford RJ
    Med Decis Making; 1990; 10(4):288-93. PubMed ID: 2146459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
    Crossley JA; Aitken DA; Berry E; Connor JM
    J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attitudes of women of childbearing age towards prenatal diagnosis in southeastern France.
    Julian-Reynier C; Macquart-Moulin G; Moatti JP; Loundou A; Aurran Y; Chabal F; Aymé S
    Prenat Diagn; 1993 Jul; 13(7):613-27. PubMed ID: 8415427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Down's syndrome risk assessment in Denmark--secondary publication].
    Ekelund CK; Andersen HJ; Christensen J; Ersbak V; Farlie R; Henriques C; Holmskov A; Jensen LN; Jørgensen FS; Hessellund A; Larsen T; Olesen AW; Pedersen OB; Poulsen H; Ramb J; Skibsted L; Skovbo P; Sommer S; Sperling L; Sundberg K; Juul SV; Zingenberg H; Tabor A
    Ugeskr Laeger; 2010 Jun; 172(23):1759-61. PubMed ID: 20552746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
    Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
    Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States.
    Khoshnood B; Pryde P; Blondel B; Lee KS
    Rev Epidemiol Sante Publique; 2003 Dec; 51(6):617-27. PubMed ID: 14967994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chorionic villus sampling for Down's syndrome.
    Lancet; 1991 Jun; 337(8755):1480-1. PubMed ID: 1675344
    [No Abstract]   [Full Text] [Related]  

  • 9. Ethnic and socio-economic differences in uptake of prenatal diagnostic tests for Down's syndrome.
    Fransen MP; Wildschut HI; Mackenbach JP; Steegers EA; Galjaard RJ; Essink-Bot ML
    Eur J Obstet Gynecol Reprod Biol; 2010 Aug; 151(2):158-62. PubMed ID: 20546988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance of amniocentesis by women in the state of Montana (USA) who are screen positive for Down's syndrome.
    Priest JH; FitzGerald JM; Haag MM; Streets K; Vanisko M; Johnson JP
    J Med Screen; 1998; 5(4):178-82. PubMed ID: 9934647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal genetic diagnosis of Down's syndrome.
    Abbott MA; Benn P
    Expert Rev Mol Diagn; 2002 Nov; 2(6):605-15. PubMed ID: 12465456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal Risk Assessment and Diagnosis of Down Syndrome: Strategies for Communicating Well with Patients.
    Schwartz E; Vellody K
    AMA J Ethics; 2016 Apr; 18(4):359-64. PubMed ID: 27099184
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The development of screening tests for Down syndrome and the application of these tests in the Israeli health system].
    Weiner Z; Buda I; Halberthal M
    Harefuah; 2013 Sep; 152(9):543-6, 563. PubMed ID: 24364096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal detection of Down's syndrome by rapid aneuploidy testing for chromosomes 13, 18, and 21 by FISH or PCR without a full karyotype: a cytogenetic risk assessment.
    Caine A; Maltby AE; Parkin CA; Waters JJ; Crolla JA;
    Lancet; 2005 Jul 9-15; 366(9480):123-8. PubMed ID: 16005334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similarities in women's decision-making in the U.S. and U.K. during prenatal screening for Down's syndrome.
    Haddow JE; Palomaki GE
    Prenat Diagn; 1996 Dec; 16(12):1161-2. PubMed ID: 8994255
    [No Abstract]   [Full Text] [Related]  

  • 18. [The decision-making process of pregnant women with positive reaction to maternal serum screening for Down's syndrome when facing amniocentesis].
    Chou CC; Lee TY; Shih FJ
    Hu Li Yan Jiu; 2001 Feb; 9(1):15-27. PubMed ID: 11548212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost utility of prenatal diagnosis and the risk-based threshold.
    Harris RA; Washington AE; Nease RF; Kuppermann M
    Lancet; 2004 Jan; 363(9405):276-82. PubMed ID: 14751700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prenatal investigations for Down's syndrome: medical-technical considerations and dilemmas arising from current screening methods].
    Grijseels EW; Laudy JA; Galjaard RJ; Wildschut HI
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2166-71. PubMed ID: 15559409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.